Treatment Selection for Early to Intermediate Hepatocellular Carcinoma
Source abstract
Abstract
Many guidelines and standard therapies have been published for the treatment of hepatocellular carcinoma (HCC). Multiple options for the treatment of early to intermediate-stage HCC have resulted in several differences between the guidelines. In addition, more than a few non-standard therapies have been used in a real-world clinical setting. Radiofrequency ablation or chemotherapy, including hepatic arterial infusion chemotherapy and molecular target agents, are sometimes selected for the treatment of intermediate HCC, whereas in many guidelines, the recommended therapy for these patients is transcatheter arterial chemoembolization. The present status of these topics is reviewed and summarized.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hepatocellular Carcinoma Treatment and Prognosis · Liver Disease Diagnosis and Treatment · Liver Disease and Transplantation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Gastroenterology, Okayama City Hospital, Okayama 700-8558, Japan
Mitsui Memorial Hospital, Tokyo 101-8643, Japan
Kanazawa University, Kanazawa 920-1192, Japan
Hyogo College of Medicine, Hyogo 663-8501, Japan
Taipei Veterans General Hospital, Taipei 11217, Taiwan
Samsun Medical Center, Seoul 06351, Korea
Seoul National University Hospital, Seoul 03080, Korea
Asan Medical Center, Seoul 05505, Korea
TATA Memorial Hospital, Mumbai 400 012, India
Rela Institute and Medical Center, Chennai 600 044, India
Yokokura Hospital, Fukuoka 839-0295, Japan
References (29)
Show source-provided references
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods10.1002/ijc.31937 ↗
2. Changing etiology of hepatocellular carcinoma10.1007/s00535-019-01622-5 ↗
3. Evolution of prognostic factors in hepatocellular carcinoma in Japan10.1111/j.1365-2036.2009.04179.x ↗
4. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update10.1007/s12072-017-9799-9 ↗
5. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma10.21037/hbsn.2017.11.01 ↗
6. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182–236.10.1016/j.jhep.2018.03.019 ↗
7. (2018). Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J. Formos. Med Assoc., 117, 381–403.
8. AASLD guidelines for the treatment of hepatocellular carcinoma10.1002/hep.29086 ↗
9. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases10.1002/hep.29913 ↗
10. (2019). 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J. Radiol., 20, 1042–1113.10.3348/kjr.2019.0140 ↗
11. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update10.1111/hepr.13411 ↗
12. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis10.1159/000331411 ↗
13. Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma10.1016/j.ejrad.2014.06.031 ↗
14. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma10.1186/1471-2407-14-849 ↗
15. Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma10.1159/000440627 ↗
16. Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma10.1111/hepr.12566 ↗
17. Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma10.1111/jgh.13586 ↗
18. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma10.1080/00365521.2018.1548645 ↗
19. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study10.1016/j.jfma.2017.03.014 ↗
20. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma10.1155/2019/6298502 ↗
21. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies10.1159/000502479 ↗
22. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a subclassification to facilitate treatment decisions
23. Sorafenib in advanced hepatocellular carcinoma10.1056/NEJMoa0708857 ↗
24. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial10.1016/S0140-6736(18)30207-1 ↗
25. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial10.1016/S1470-2045(18)30937-9 ↗
26. Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., and Ida, H. (2019). Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers, 11.10.20944/preprints201906.0285.v1 ↗
27. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan10.1038/bjc.2013.542 ↗
28. Sorafenib Plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy Versus Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial10.1016/S2468-1253(18)30078-5 ↗
29. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child–Pugh B cirrhosis10.1111/cas.12992 ↗